Article(id=1329529030371553823, tenantId=1146029695717560320, journalId=1319690329412173987, issueId=1329529021181833654, articleNumber=null, orderNo=null, doi=10.13683/j.wph.2024.07.003, pmid=null, cstr=null, oa=null, hot=null, price=null, onlineType=0, articleFormat=0, articleType=null, articleTypeStr=null, receivedDate=1714406400000, receivedDateStr=2024-04-30, revisedDate=null, revisedDateStr=null, acceptedDate=null, acceptedDateStr=null, onlineDate=1794914022294, onlineDateStr=2026-11-17, pubDate=1720540800000, pubDateStr=2024-07-10, doiRegisterDate=null, doiRegisterDateStr=null, onlineIssueDate=1794914022294, onlineIssueDateStr=2026-11-17, onlineJustAcceptDate=null, onlineJustAcceptDateStr=null, onlineFirstDate=null, onlineFirstDateStr=null, sourceXml=null, magXml=null, createTime=1794914022294, creator=13701087609, updateTime=1794914022294, updator=13701087609, issue=Issue{id=1329529021181833654, tenantId=1146029695717560320, journalId=1319690329412173987, year='2024', volume='45', issue='7', pageStart='697', pageEnd='798', issueExtLink='null', onlineDate='null', pubDate='1720540800000', pubDateStr='2024-07-10', beforeIssueId=null, nextIssueId=null, price=null, status=1, issueComplete=1, articleOrder=1, issueType=-1, specialIssue=null, createTime=1794914020104, creator='13701087609', updateTime=1794988140586, updator='13701087609', preIssue=null, nextIssue=null, articleTotal=null, ext={EN=IssueExt(id=1329839905410233043, tenantId=1146029695717560320, journalId=1319690329412173987, issueId=1329529021181833654, language=EN, specialIssueTitle=, coverIllustrator=null, specialIssueEditor=, specialIssueAbout=), CN=IssueExt(id=1329839905410233044, tenantId=1146029695717560320, journalId=1319690329412173987, issueId=1329529021181833654, language=CN, specialIssueTitle=, coverIllustrator=null, specialIssueEditor=, specialIssueAbout=)}, issueFiles=null, downloadFileDto=null}, startPage=710, endPage=718, ext={EN=ArticleExt(id=1329529030656766496, articleId=1329529030371553823, tenantId=1146029695717560320, journalId=1319690329412173987, language=EN, title=Clinical research progress of anti-angiogenic tyrosine kinase inhibitors in solid tumors, columnId=1325221107665612978, journalTitle=World Clinical Drug, columnName=Topic, runingTitle=null, highlight=null, articleAbstract=

Angiogenesis plays a key role in the growth, local invasion and distant metastasis of a variety of solid tumors. At present, anti-angiogenesis drugs can be divided into three types: small-molecule multi-target, macromolecule single-target and endogenous pan-target angiogenesis inhibitors. Among them, small molecule anti-angiogenesis inhibitors mainly inhibit tumor angiogenesis by simultaneously or sequentially targeting multiple growth factors/pathways, and can effectively inhibit drug resistance generated by tumor cells. At the same time, small molecule anti-angiogenesis inhibitors have the advantages of good tissue permeability and convenient administration. At present, it has been widely used in the combination therapy of various solid tumors. This paper reviewed the targeted therapy of small molecule anti-angiogenic tyrosine kinase inhibitors and their clinical progress and safety in multiple solid tumors.

, authors=Rui XU1, Jiajia QIAN1, Cong RUAN1, Qiru WANG1, Qing ZHAI1, 2, 3, *, authorsList=Rui XU, Jiajia QIAN, Cong RUAN, Qiru WANG, Qing ZHAI, authorCompany=null, correspAuthors=Qing ZHAI, authorNote=null, correspAuthorsNote=null, copyrightStatement=null, copyrightOwner=null, extLink=null, articleAbsUrl=null, sourceXml=null, magXml=null, pdfUrl=null, pdf=null, pdfFileSize=null, pdfExtLink=null, richHtmlUrl=null, mobilePdfUrl=null, reviewReport=null, pdfFirstPage=null, abstractGraph=null, abstractGraphContent=null, abstractVideo=null, citation=null, cebUrl=null, magXmlContent=null, mapNumber=null, fund=null), CN=ArticleExt(id=1329529031046836769, articleId=1329529030371553823, tenantId=1146029695717560320, journalId=1319690329412173987, language=CN, title=抗血管生成酪氨酸激酶抑制剂在实体瘤中的临床研究进展, columnId=1325221107824996532, journalTitle=世界临床药物, columnName=医药专论, runingTitle=null, highlight=null, articleAbstract=

新生血管的生成在多种实体肿瘤的生长、局部浸润以及远处转移中发挥关键作用。目前抗血管生成药物可为小分子多靶点、大分子单靶点和内源性泛靶点血管生成抑制剂3类。其中小分子抗血管生成抑制剂主要通过同时或序贯靶向多个生长因子/通路,从而抑制肿瘤血管新生,能有效抑制肿瘤细胞产生的耐药性。同时小分子抗血管生成抑制剂具有组织渗透性佳以及服用方便等优点,目前已被广泛用于多种实体肿瘤的联合治疗。该文对小分子抗血管生成酪氨酸激酶抑制剂的靶向治疗,以及其在多种实体瘤中的临床研究进展、安全性作一综述。

, authors=徐蕊1, 钱佳佳1, 阮聪1, 王祺茹1, 翟青1, 2, 3, *, authorsList=徐蕊, 钱佳佳, 阮聪, 王祺茹, 翟青, authorCompany=null, correspAuthors=翟青, authorNote=

徐蕊,主管药师,研究方向:肿瘤药学。

, correspAuthorsNote=
翟青,主任药师,博士研究生导师,研究方向:肿瘤药学。
, copyrightStatement=null, copyrightOwner=null, extLink=null, articleAbsUrl=null, sourceXml=Skwhja3IaXSmlYJFxr36TA==, magXml=f3nMuTIbFBvjW8Wz5XrstA==, pdfUrl=null, pdf=sFBZbU8jqd/q6jQfqqaq4g==, pdfFileSize=2039955, pdfExtLink=null, richHtmlUrl=null, mobilePdfUrl=null, reviewReport=null, pdfFirstPage=null, abstractGraph=null, abstractGraphContent=null, abstractVideo=null, citation=null, cebUrl=null, magXmlContent=V6EpQ8SFCMssxFyvFO7LEA==, mapNumber=null, fund=null)}, authors=[Author(id=1329529031680176684, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529030371553823, orderNo=0, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1329529031801811503, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529030371553823, authorId=1329529031680176684, language=EN, stringName=Rui XU, firstName=Rui, middleName=null, lastName=XU, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, address=1.Department of Pharmacy, Fudan University Shanghai Cancer Center Minhang Branch, Shanghai 200240, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1329529031915057712, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529030371553823, authorId=1329529031680176684, language=CN, stringName=徐蕊, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, address=1.复旦大学附属肿瘤医院闵行院区药剂科,上海 200240, bio={"content":"

徐蕊,主管药师,研究方向:肿瘤药学。

"}, bioImg=null, bioContent=

徐蕊,主管药师,研究方向:肿瘤药学。

, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1329529031340438050, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529030371553823, xref=1., ext=[AuthorCompanyExt(id=1329529031348826659, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529030371553823, companyId=1329529031340438050, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.Department of Pharmacy, Fudan University Shanghai Cancer Center Minhang Branch, Shanghai 200240, China), AuthorCompanyExt(id=1329529031386575396, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529030371553823, companyId=1329529031340438050, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.复旦大学附属肿瘤医院闵行院区药剂科,上海 200240)])]), Author(id=1329529032019915314, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529030371553823, orderNo=1, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1329529032158327348, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529030371553823, authorId=1329529032019915314, language=EN, stringName=Jiajia QIAN, firstName=Jiajia, middleName=null, lastName=QIAN, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, address=1.Department of Pharmacy, Fudan University Shanghai Cancer Center Minhang Branch, Shanghai 200240, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1329529032233824821, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529030371553823, authorId=1329529032019915314, language=CN, stringName=钱佳佳, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, address=1.复旦大学附属肿瘤医院闵行院区药剂科,上海 200240, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1329529031340438050, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529030371553823, xref=1., ext=[AuthorCompanyExt(id=1329529031348826659, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529030371553823, companyId=1329529031340438050, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.Department of Pharmacy, Fudan University Shanghai Cancer Center Minhang Branch, Shanghai 200240, China), AuthorCompanyExt(id=1329529031386575396, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529030371553823, companyId=1329529031340438050, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.复旦大学附属肿瘤医院闵行院区药剂科,上海 200240)])]), Author(id=1329529032309322295, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529030371553823, orderNo=2, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1329529032376431161, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529030371553823, authorId=1329529032309322295, language=EN, stringName=Cong RUAN, firstName=Cong, middleName=null, lastName=RUAN, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, address=1.Department of Pharmacy, Fudan University Shanghai Cancer Center Minhang Branch, Shanghai 200240, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1329529032456122938, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529030371553823, authorId=1329529032309322295, language=CN, stringName=阮聪, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, address=1.复旦大学附属肿瘤医院闵行院区药剂科,上海 200240, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1329529031340438050, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529030371553823, xref=1., ext=[AuthorCompanyExt(id=1329529031348826659, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529030371553823, companyId=1329529031340438050, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.Department of Pharmacy, Fudan University Shanghai Cancer Center Minhang Branch, Shanghai 200240, China), AuthorCompanyExt(id=1329529031386575396, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529030371553823, companyId=1329529031340438050, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.复旦大学附属肿瘤医院闵行院区药剂科,上海 200240)])]), Author(id=1329529032540009021, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529030371553823, orderNo=3, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1329529032598729279, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529030371553823, authorId=1329529032540009021, language=EN, stringName=Qiru WANG, firstName=Qiru, middleName=null, lastName=WANG, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, address=1.Department of Pharmacy, Fudan University Shanghai Cancer Center Minhang Branch, Shanghai 200240, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1329529032674226752, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529030371553823, authorId=1329529032540009021, language=CN, stringName=王祺茹, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, address=1.复旦大学附属肿瘤医院闵行院区药剂科,上海 200240, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1329529031340438050, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529030371553823, xref=1., ext=[AuthorCompanyExt(id=1329529031348826659, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529030371553823, companyId=1329529031340438050, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.Department of Pharmacy, Fudan University Shanghai Cancer Center Minhang Branch, Shanghai 200240, China), AuthorCompanyExt(id=1329529031386575396, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529030371553823, companyId=1329529031340438050, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.复旦大学附属肿瘤医院闵行院区药剂科,上海 200240)])]), Author(id=1329529032758112834, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529030371553823, orderNo=4, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=1, authorType=1, ext={EN=AuthorExt(id=1329529032900719174, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529030371553823, authorId=1329529032758112834, language=EN, stringName=Qing ZHAI, firstName=Qing, middleName=null, lastName=ZHAI, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, 2, 3, *, address=1.Department of Pharmacy, Fudan University Shanghai Cancer Center Minhang Branch, Shanghai 200240, China
2.Department of Pharmacy, Fudan University Shanghai Cancer Center, Shanghai 200032, China
3.Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1329529032967828039, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529030371553823, authorId=1329529032758112834, language=CN, stringName=翟青, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, 2, 3, *, address=1.复旦大学附属肿瘤医院闵行院区药剂科,上海 200240
2.复旦大学附属肿瘤医院药剂科,上海 200032
3.复旦大学上海医学院肿瘤学系,上海 200032, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1329529031340438050, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529030371553823, xref=1., ext=[AuthorCompanyExt(id=1329529031348826659, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529030371553823, companyId=1329529031340438050, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.Department of Pharmacy, Fudan University Shanghai Cancer Center Minhang Branch, Shanghai 200240, China), AuthorCompanyExt(id=1329529031386575396, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529030371553823, companyId=1329529031340438050, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.复旦大学附属肿瘤医院闵行院区药剂科,上海 200240)]), AuthorCompany(id=1329529031457878565, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529030371553823, xref=2., ext=[AuthorCompanyExt(id=1329529031470461478, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529030371553823, companyId=1329529031457878565, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.Department of Pharmacy, Fudan University Shanghai Cancer Center, Shanghai 200032, China), AuthorCompanyExt(id=1329529031478850087, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529030371553823, companyId=1329529031457878565, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.复旦大学附属肿瘤医院药剂科,上海 200032)]), AuthorCompany(id=1329529031550153256, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529030371553823, xref=3., ext=[AuthorCompanyExt(id=1329529031558541865, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529030371553823, companyId=1329529031550153256, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=3.Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China), AuthorCompanyExt(id=1329529031571124778, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529030371553823, companyId=1329529031550153256, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=3.复旦大学上海医学院肿瘤学系,上海 200032)])])], keywords=[Keyword(id=1329529033097851464, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529030371553823, language=EN, orderNo=1, keyword=solid tumors), Keyword(id=1329529033211097673, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529030371553823, language=EN, orderNo=2, keyword=small molecules), Keyword(id=1329529033299178058, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529030371553823, language=EN, orderNo=3, keyword=antiangiogenic inhibitors), Keyword(id=1329529033383064139, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529030371553823, language=EN, orderNo=4, keyword=tyrosine kinase inhibitors), Keyword(id=1329529033454367309, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529030371553823, language=CN, orderNo=1, keyword=实体瘤), Keyword(id=1329529033567613519, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529030371553823, language=CN, orderNo=2, keyword=小分子), Keyword(id=1329529033680859728, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529030371553823, language=CN, orderNo=3, keyword=抗血管生成抑制剂), Keyword(id=1329529033810883153, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529030371553823, language=CN, orderNo=4, keyword=酪氨酸激酶抑制剂)], refs=[Reference(id=1329529034330976854, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529030371553823, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[1], rfOrder=0, authorNames=null, journalName=null, refType=null, unstructuredReference=Qin S, Li A, Yi M, et al. Recent advances on anti-angiogenesis receptor tyrosine kinase inhibitors in cancer therapy[J]. J Hematol Oncol, 2019, 12(1): 27., articleTitle=null, refAbstract=null), Reference(id=1329529034410668631, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529030371553823, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[2], rfOrder=1, authorNames=null, journalName=null, refType=null, unstructuredReference=姜婧琦, 宋雨童, 卢育彤, 等. 抗血管生成靶向药物在肿瘤治疗中的研究进展[J]. 山东医药, 2022, 62(22): 86-90., articleTitle=null, refAbstract=null), Reference(id=1329529034498749016, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529030371553823, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[3], rfOrder=2, authorNames=null, journalName=null, refType=null, unstructuredReference=Li SJ, Chen JX, Sun ZJ. Improving antitumor immunity using antiangiogenic agents: mechanistic insights, current progress, and clinical challenges[J]. Cancer Commun (Lond), 2021, 41(9): 830-850., articleTitle=null, refAbstract=null), Reference(id=1329529034574246489, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529030371553823, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[4], rfOrder=3, authorNames=null, journalName=null, refType=null, unstructuredReference=Pu X, Xiao Z, Li J, et al. Anlotinib plus docetaxel vs docetaxel alone for advanced non-small-cell lung cancer patients who failed first-line treatment: a multicenter, randomized phase Ⅱtrial[J]. Lung Cancer, 2024, 191: 107538., articleTitle=null, refAbstract=null), Reference(id=1329529034641355354, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529030371553823, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[5], rfOrder=4, authorNames=null, journalName=null, refType=null, unstructuredReference=Zhang L, Wang L, Wang J, et al. Anlotinib plus icotinib as a potential treatment option for EGFR-mutated advanced non-squamous non-small cell lung cancer with concurrent mutations: final analysis of the prospective phase 2, multicenter ALTER-L004 study[J]. Mol Cancer, 2023, 22(1): 124., articleTitle=null, refAbstract=null), Reference(id=1329529034712658523, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529030371553823, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[6], rfOrder=5, authorNames=null, journalName=null, refType=null, unstructuredReference=Lu S, Chang J, Liu X, et al. Randomized, double-blind, placebocontrolled, multicenter phase Ⅱ study of fruquintinib after two prior chemotherapy regimens in Chinese patients with advanced nonsquamous nonsmall-cell lung cancer[J]. J Clin Oncol, 2018, 36(12): 1207-1217., articleTitle=null, refAbstract=null), Reference(id=1329529034792350300, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529030371553823, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[7], rfOrder=6, authorNames=null, journalName=null, refType=null, unstructuredReference=Lu S, Chen G, Sun Y, et al. A Phase Ⅲ, randomized, double-blind, placebo-controlled, multicenter study of fruquintinib in Chinese patients with advanced nonsquamous non-small-cell lung cancer—the FALUCA study[J]. Lung Cancer, 2020, 146: 252-262., articleTitle=null, refAbstract=null), Reference(id=1329529034863653469, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529030371553823, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[8], rfOrder=7, authorNames=null, journalName=null, refType=null, unstructuredReference=Xia H, Zhang H, Ruan Z, et al. Neoadjuvant camrelizumab (an anti-PD-1 antibody) plus chemotherapy or apatinib (a VEGFR-2 inhibitor) for initially unresectable stage Ⅱ—Ⅲnon-small-cell lung cancer: a multicentre, two-arm, phase 2 exploratory study[J]. Signal Transduct Target Ther, 2024, 9(1): 145., articleTitle=null, refAbstract=null), Reference(id=1329529034976899678, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529030371553823, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[9], rfOrder=8, authorNames=null, journalName=null, refType=null, unstructuredReference=Pu X, Lin G, Xiao M, et al. Camrelizumab combined with apatinib and nanoparticle albumin-bound paclitaxel in lung adenocarcinoma (CAPAP-lung): a single-arm phase Ⅱstudy[J]. EClinicalMedicine, 2024, 67: 102403., articleTitle=null, refAbstract=null), Reference(id=1329529035056591455, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529030371553823, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[10], rfOrder=9, authorNames=null, journalName=null, refType=null, unstructuredReference=Ma S, He Z, Liu Y, et al. Sintilimab plus anlotinib as second or further-line therapy for extensive disease small cell lung cancer: a phase 2 investigator-initiated non-randomized controlled trial[J]. EClinicalMedicine, 2024, 14(70): 102543., articleTitle=null, refAbstract=null), Reference(id=1329529035144671840, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529030371553823, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[11], rfOrder=10, authorNames=null, journalName=null, refType=null, unstructuredReference=Liu J, Liu Q, Li Y, et al. Efficacy and safety of camrelizumab combined with apatinib in advanced triple-negative breast cancer: an open-label phase Ⅱ trial[J]. J Immunother Cancer, 2020, 8(1): e000696., articleTitle=null, refAbstract=null), Reference(id=1329529035253723745, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529030371553823, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[12], rfOrder=11, authorNames=null, journalName=null, refType=null, unstructuredReference=Zeng T, Sun C, Liang Y, et al. A real-world multicentre retrospective study of low-dose apatinib for human epidermal growth factor receptor 2-negative metastatic breast cancer[J]. Cancers (Basel), 2022, 14(17): 4084., articleTitle=null, refAbstract=null), Reference(id=1329529035333415522, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529030371553823, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[13], rfOrder=12, authorNames=null, journalName=null, refType=null, unstructuredReference=Liu Y, Wang W, Yin R, et al. A phase 1 trial of fuzuloparib in combination with apatinib for advanced ovarian and triple-negative breast cancer: efficacy, safety, pharmacokinetics and germline BRCA mutation analysis[J]. Bio Med Central Med, 2023, 21(1): 376., articleTitle=null, refAbstract=null), Reference(id=1329529035413107299, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529030371553823, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[14], rfOrder=13, authorNames=null, journalName=null, refType=null, unstructuredReference=中国临床肿瘤协会(CSCO)妇科肿瘤专家委员会. 抗血管生成小分子酪氨酸激酶抑制剂在复发转移或晚期妇科肿瘤临床应用的中国专家共识(2022版)[J]. 中国癌症防治杂志, 2023, 15(1): 1-10., articleTitle=null, refAbstract=null), Reference(id=1329529035488604772, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529030371553823, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[15], rfOrder=14, authorNames=null, journalName=null, refType=null, unstructuredReference=Shen W, Jing C, Tian W, et al. Anlotinib in patients with recurrent platinum resistant/refractory ovarian cancer: a prospective, single arm, phase Ⅱ study[J]. Int J Gynecol Cancer, 2023, 33(11): 1764-1770., articleTitle=null, refAbstract=null), Reference(id=1329529035606045285, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529030371553823, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[16], rfOrder=15, authorNames=null, journalName=null, refType=null, unstructuredReference=Xu Q, Wang J, Sun Y, et al. Efficacy and safety of sintilimab plus anlotinib for PD-L1-positive recurrent or metastatic cervical cancer: a multicenter, single-arm, prospective phase Ⅱ trial[J]. J Clin Oncol, 2022, 40(16): 1795-1805., articleTitle=null, refAbstract=null), Reference(id=1329529035769623142, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529030371553823, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[17], rfOrder=16, authorNames=null, journalName=null, refType=null, unstructuredReference=Lan C, Shen J, Wang Y, et al. Camrelizumab plus apatinib in patients with advanced cervical cancer (CLAP): a multicenter, open-label, single-arm, phase Ⅱ trial[J]. J Clin Oncol, 2020, 38(34): 4095-4106., articleTitle=null, refAbstract=null), Reference(id=1329529035861897831, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529030371553823, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[18], rfOrder=17, authorNames=null, journalName=null, refType=null, unstructuredReference=谢玲玲, 林仲秋. 《2024NCCN子宫肿瘤临床实践指南(第1版)》解读[J]. 中国实用妇科与产科杂志, 2023, 39(11): 1122-1127., articleTitle=null, refAbstract=null), Reference(id=1329529035941589608, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529030371553823, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[19], rfOrder=18, authorNames=null, journalName=null, refType=null, unstructuredReference=Yuan G, Li Z, Ye F, et al. A multicenter, single-arm, phase 2 study of surufatinib plus toripalimab for patients with advanced endometrial cancer[EB/OL]. [2023-12-20]. https://meetings.asco.org/abstracts-presentations/223054, articleTitle=null, refAbstract=null), Reference(id=1329529036025475689, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529030371553823, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[20], rfOrder=19, authorNames=null, journalName=null, refType=null, unstructuredReference=Li Y, Feng H, Ren P, et al. Safety and efficacy of apatinib monotherapy for unresectable, metastatic esophageal cancer: a single-arm, open-label, phase Ⅱ study[J]. Oncologist, 2020, 25(10): e1464-e1472., articleTitle=null, refAbstract=null), Reference(id=1329529036117750378, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529030371553823, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[21], rfOrder=20, authorNames=null, journalName=null, refType=null, unstructuredReference=Shen L, Lu M, Chen Z, et al. Phase Ⅱ trial of surufatinib plus toripalimab for disease progression after first-line chemotherapy with platinum and fluoropyrimidine in advanced gastric or gastroesophageal junction adenocarcinoma[EB/OL]. [2023-12-20]. https://meetings.asco.org/abstracts-presentations/199210, articleTitle=null, refAbstract=null), Reference(id=1329529036193247851, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529030371553823, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[22], rfOrder=21, authorNames=null, journalName=null, refType=null, unstructuredReference=Yan T, Huang C, Peng C, et al. A multi-center retrospective study on the efficacy and safety of regorafenib vs. regorafenib combined with PD-1 inhibitors as a second-line therapy in patients with advanced hepatocellular carcinoma[J]. Ann Transl Med, 2023, 11(2): 109., articleTitle=null, refAbstract=null), Reference(id=1329529036268745324, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529030371553823, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[23], rfOrder=22, authorNames=null, journalName=null, refType=null, unstructuredReference=蔡宇, 赵长海, 罗利琼. 卡瑞利珠单抗联合安罗替尼治疗中晚期肝癌的疗效和安全性[J]. 循证医学, 2022, 22(4): 237-242., articleTitle=null, refAbstract=null), Reference(id=1329529036402963053, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529030371553823, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[24], rfOrder=23, authorNames=null, journalName=null, refType=null, unstructuredReference=Dai GH, Jia R, Si H, et al. A phase 1b/2 study of surufatinib plus camrelizumab, nab-paclitaxel, and S-1 (NASCA) as first-line therapy for metastatic pancreatic adenocarcinoma (mPDAC)[EB/OL]. [2023-12-20]. https://meetings.asco.org/abstracts-presentations/226583, articleTitle=null, refAbstract=null), Reference(id=1329529036465877614, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529030371553823, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[25], rfOrder=24, authorNames=null, journalName=null, refType=null, unstructuredReference=Dasari A, Lonardi S, Garcia-Carbonero R, et al. Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study[J]. Lancet, 2023, 402(10395): 41-53., articleTitle=null, refAbstract=null), Reference(id=1329529036532986479, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529030371553823, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[26], rfOrder=25, authorNames=null, journalName=null, refType=null, unstructuredReference=Bourien H, Lamarca A, McNamara MG, et al. Druggable molecular alterations in bile duct cancer: potential and current therapeutic applications in clinical trials[J]. Expert Opin Investig Drugs, 2021, 30(9): 975-983., articleTitle=null, refAbstract=null), Reference(id=1329529036621066864, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529030371553823, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[27], rfOrder=26, authorNames=null, journalName=null, refType=null, unstructuredReference=中国临床肿瘤学会指南工作委员会. 中国临床肿瘤学会(CSCO)胆道恶性肿瘤诊疗指南2023[M]. 北京: 人民卫生出版社, 2023., articleTitle=null, refAbstract=null), Reference(id=1329529036717535857, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529030371553823, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[28], rfOrder=27, authorNames=null, journalName=null, refType=null, unstructuredReference=Goyal L, Meric-Bernstam F, Hollebecque A, et al. Futibatinib for FGFR2-rearranged intrahepatic cholangiocarcinoma[J]. N Engl J Med, 2023, 388(3): 228-239., articleTitle=null, refAbstract=null), Reference(id=1329529036797227634, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529030371553823, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[29], rfOrder=28, authorNames=null, journalName=null, refType=null, unstructuredReference=Maroto P, Porta C, Capdevila J, et al. Cabozantinib for the treatment of solid tumors: a systematic review[J]. Ther Adv Med Oncol, 2022, 14: 17588359221107112., articleTitle=null, refAbstract=null), Reference(id=1329529036872725107, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529030371553823, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[30], rfOrder=29, authorNames=null, journalName=null, refType=null, unstructuredReference=Chen J, Ji Q, Bai C, et al. Surufatinib in Chinese patients with locally advanced or metastatic differentiated thyroid cancer and medullary thyroid cancer: a multicenter, open-label, phase Ⅱ trial[J]. Thyroid, 2020, 30(9): 1245-1253., articleTitle=null, refAbstract=null), Reference(id=1329529036948222580, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529030371553823, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[31], rfOrder=30, authorNames=null, journalName=null, refType=null, unstructuredReference=Chen JY, Huang NS, Wei WJ, et al. The efficacy and safety of surufatinib combined with anti PD-1 antibody toripalimab in neoadjuvant treatment of locally advanced differentiated thyroid cancer: a phase Ⅱ study[J]. Ann Surg Oncol, 2023, 30(12): 7172-7180., articleTitle=null, refAbstract=null), Reference(id=1329529037023720053, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529030371553823, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[32], rfOrder=31, authorNames=null, journalName=null, refType=null, unstructuredReference=Dierks C, Seufert J, Aumann K, et al. Combination of lenvatinib and pembrolizumab is an effective treatment option for anaplastic and poorly differentiated thyroid carcinoma[J]. Thyroid, 2021, 31(7): 1076-1085., articleTitle=null, refAbstract=null), Reference(id=1329529037090828918, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529030371553823, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[33], rfOrder=32, authorNames=null, journalName=null, refType=null, unstructuredReference=中国临床肿瘤学会指南工作委员会. 中国临床肿瘤学会(CSCO)软组织肉瘤诊疗指南(2022)[M]. 北京: 人民卫生出版社, 2022., articleTitle=null, refAbstract=null), Reference(id=1329529037157937783, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529030371553823, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[34], rfOrder=33, authorNames=null, journalName=null, refType=null, unstructuredReference=Xu B, Pan Q, Pan H, et al. Anlotinib as a maintenance treatment for advanced soft tissue sarcoma after first-line chemotherapy (ALTER-S006): a multicentre, open-label, single-arm, phase 2 trial[J]. EClinicalMedicine, 2023, 64: 102240., articleTitle=null, refAbstract=null), Reference(id=1329529037283766904, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529030371553823, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[35], rfOrder=34, authorNames=null, journalName=null, refType=null, unstructuredReference=Liu Z, Wang X, Wang J, et al. Gemcitabine plus anlotinib is effective and safe compared to gemcitabine plus docetaxel in advanced soft tissue sarcoma[J]. Front Oncol, 2022, 12: 922127., articleTitle=null, refAbstract=null), Reference(id=1329529037355070073, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529030371553823, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[36], rfOrder=35, authorNames=null, journalName=null, refType=null, unstructuredReference=Endo M, Kataoka T, Fujiwara T, et al. Protocol for the 2ND-STEP study, Japan Clinical Oncology Group study JCOG1802: a randomized phase Ⅱ trial of second-line treatment for advanced soft tissue sarcoma comparing trabectedin, eribulin and pazopanib[J]. Bio Med Central Cancer, 2023, 23(1): 219., articleTitle=null, refAbstract=null), Reference(id=1329529037417984634, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529030371553823, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[37], rfOrder=36, authorNames=null, journalName=null, refType=null, unstructuredReference=Penel N, Mir O, Wallet J, et al. A double-blind placebo controlled randomized phase Ⅱ trial assessing the activity and safety of regorafenib in non-adipocytic sarcoma patients previously treated with both chemotherapy and pazopanib[J]. Eur J Cancer, 2020, 126: 45-55., articleTitle=null, refAbstract=null), Reference(id=1329529037493482107, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529030371553823, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[38], rfOrder=37, authorNames=null, journalName=null, refType=null, unstructuredReference=Motzer RJ, Porta C, Eto M, et al. Lenvatinib plus pembrolizumab versus sunitinib in first-line treatment of advanced renal cell carcinoma: final prespecified overall survival analysis of CLEAR, a phase Ⅲ study[J]. J Clin Oncol, 2024, 42(11): 1222-1228., articleTitle=null, refAbstract=null), Reference(id=1329529037552202364, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529030371553823, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[39], rfOrder=38, authorNames=null, journalName=null, refType=null, unstructuredReference=李长岭, 齐隽, 陈立军, 等. 晚期肾透明细胞癌一线靶向治疗的优化选择中国专家共识(2022)[J]. 临床泌尿外科杂志, 2022, 37(5): 329-337., articleTitle=null, refAbstract=null), Reference(id=1329529037636088445, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529030371553823, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[40], rfOrder=39, authorNames=null, journalName=null, refType=null, unstructuredReference=Loriot Y, Matsubara N, Park SH, et al. Erdafitinib or chemotherapy in advanced or metastatic urothelial carcinoma[J]. N Engl J Med, 2023, 389(21): 1961-1971., articleTitle=null, refAbstract=null), Reference(id=1329529037724168830, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529030371553823, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[41], rfOrder=40, authorNames=null, journalName=null, refType=null, unstructuredReference=Liang H, Jiang YF, Liu GY, et al. Camrelizumab and apatinib plus induction chemotherapy and concurrent chemoradiotherapy in stage N3 nasopharyngeal carcinoma: a phase 2 clinical trial[J]. Nat Commun, 2024, 15(1): 1029., articleTitle=null, refAbstract=null), Reference(id=1329529037787083391, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529030371553823, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[42], rfOrder=41, authorNames=null, journalName=null, refType=null, unstructuredReference=Ding X, Zhang WJ, You R, et al. Camrelizumab plus apatinib in patients with recurrent or metastatic nasopharyngeal carcinoma: an open-label, single-arm, phase Ⅱ study[J]. J Clin Oncol, 2023, 41(14): 2571-2582., articleTitle=null, refAbstract=null), Reference(id=1329529037854192256, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529030371553823, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[43], rfOrder=42, authorNames=null, journalName=null, refType=null, unstructuredReference=Ding X, Hua YJ, Zou X, et al. Camrelizumab plus famitinib in patients with recurrent or metastatic nasopharyngeal carcinoma treated with PD-1 blockade: data from a multicohort phase 2 study[J]. EClinicalMedicine, 2023, 61: 102043., articleTitle=null, refAbstract=null), Reference(id=1329529037971632769, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529030371553823, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[44], rfOrder=43, authorNames=null, journalName=null, refType=null, unstructuredReference=Cao Y, Langer R, Ferrara N. Targeting angiogenesis in oncology, ophthalmology and beyond. Nat Rev Drug Discov, 2023, 22(6): 476-495., articleTitle=null, refAbstract=null), Reference(id=1329529038047130242, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529030371553823, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[45], rfOrder=44, authorNames=null, journalName=null, refType=null, unstructuredReference=Zhao Q, Wu ZE, Li B, et al. Recent advances in metabolism and toxicity of tyrosine kinase inhibitors[J]. Pharmacol Ther, 2022, 237: 108256., articleTitle=null, refAbstract=null)], funds=[Fund(id=1329529033936712274, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529030371553823, awardId=mwyjyx03, language=CN, fundingSource=上海市闵行区卫生健康系统优秀青年药学人才计划(mwyjyx03), fundOrder=null, country=null), Fund(id=1329529034070930004, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529030371553823, awardId=2022MHZ040, language=CN, fundingSource=上海市闵行区自然科学研究课题(2022MHZ040), fundOrder=null, country=null), Fund(id=1329529034200953429, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529030371553823, awardId=MHJKKPYC-2023-10, language=CN, fundingSource=上海市闵行区健康科普能力提升英才专项计划(MHJKKPYC-2023-10), fundOrder=null, country=null)], companyList=[AuthorCompany(id=1329529031340438050, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529030371553823, xref=1., ext=[AuthorCompanyExt(id=1329529031348826659, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529030371553823, companyId=1329529031340438050, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.Department of Pharmacy, Fudan University Shanghai Cancer Center Minhang Branch, Shanghai 200240, China), AuthorCompanyExt(id=1329529031386575396, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529030371553823, companyId=1329529031340438050, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.复旦大学附属肿瘤医院闵行院区药剂科,上海 200240)]), AuthorCompany(id=1329529031457878565, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529030371553823, xref=2., ext=[AuthorCompanyExt(id=1329529031470461478, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529030371553823, companyId=1329529031457878565, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.Department of Pharmacy, Fudan University Shanghai Cancer Center, Shanghai 200032, China), AuthorCompanyExt(id=1329529031478850087, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529030371553823, companyId=1329529031457878565, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.复旦大学附属肿瘤医院药剂科,上海 200032)]), AuthorCompany(id=1329529031550153256, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529030371553823, xref=3., ext=[AuthorCompanyExt(id=1329529031558541865, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529030371553823, companyId=1329529031550153256, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=3.Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China), AuthorCompanyExt(id=1329529031571124778, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529030371553823, companyId=1329529031550153256, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=3.复旦大学上海医学院肿瘤学系,上海 200032)])], figs=null, attaches=null, journal=Journal(id=1319689997550452896, delFlag=0, nameCn=世界临床药物, nameEn=World Clinical Drug, nameHistory1=null, nameHistory2=null, issn=1672-9188, eissn=null, cn=31-1939/R, coden=SLYHAA, periodic=0, language=CN, oaType=null, ccby=null, superviseOffice=null, ownerOffice=null, pubOffice=null, editorOffice=null, officeType=null, aims=null, clcCode=null, officeProv=null, officeCity=null, officeAddr=null, officeZip=null, officeEmail=null, officePhone=null, editDirector=null, officeDirector=null, officeDirectorPhone=null, officeStaffNum=null, officeEmpNum=null, coverPicUrl=9c6IkcJKa1cF20h1u6lJeQ==, journalPrice=null, startedYear=null, abbrevIsoEn=World Clinical Drug, journalRemark=null, publicationField=null, createdTime=1792568214072, updatedTime=1792747519563, createdBy=18614031015, updatedBy=13701087609, firstLetterCn=S, firstLetterEn=S, subjectCode=Medical and Pharmaceutical Sciences, subjectName=null, subjectCodeEn=Medical and Pharmaceutical Sciences, subjectNameEn=null, picCn=9c6IkcJKa1cF20h1u6lJeQ==, picEn=MRqUlTwfL6oqIHNy7eyFZQ==, jcr=null, cjcr=null, exts=[JournalExt(id=1320442059660570919, language=CN, name=世界临床药物, nameHistory1=null, nameHistory2=null, managedBy=, sponsoredBy=, publishedBy=, editorOffice=, officeProv=null, officeCity=null, officeAddr=, officeZip=, editDirector=, officeDirector=null, officePhone=null, coverPicUrl=null, journalRemark=, submitArticleUrl=null, websiteUrl=, createdTime=1792747519650, updatedTime=1792747519650, createdBy=13701087609, updatedBy=13701087609, submissionGuidelinesUrl=, submissionAuthorUrl=http://www.jwph.com.cn/journalx_sjlcyw/authorLogOn.action, submissionEditorUrl=http://www.jwph.com.cn/journalx_sjlcyw/editorLogOn.action, submissionReviewUrl=http://www.jwph.com.cn/journalx_sjlcyw/expertLogOn.action, submissionCeEditorUrl=http://www.jwph.com.cn/journalx_sjlcyw/editorInChiefLogOn.action, submissionAeEditorUrl=, option={"copyright":""}), JournalExt(id=1320442059723485480, language=EN, name=World Clinical Drug, nameHistory1=null, nameHistory2=null, managedBy=, sponsoredBy=, publishedBy=, editorOffice=, officeProv=null, officeCity=null, officeAddr=, officeZip=, editDirector=, officeDirector=null, officePhone=null, coverPicUrl=null, journalRemark=, submitArticleUrl=null, websiteUrl=, createdTime=1792747519665, updatedTime=1792747519665, createdBy=13701087609, updatedBy=13701087609, submissionGuidelinesUrl=, submissionAuthorUrl=http://www.jwph.com.cn/journalx_sjlcyw/authorLogOn.action, submissionEditorUrl=http://www.jwph.com.cn/journalx_sjlcyw/editorLogOn.action, submissionReviewUrl=http://www.jwph.com.cn/journalx_sjlcyw/expertLogOn.action, submissionCeEditorUrl=http://www.jwph.com.cn/journalx_sjlcyw/editorInChiefLogOn.action, submissionAeEditorUrl=, option={"copyright":""})], databaseList=null, tenantJournalId=1319690329412173987, websiteList=[Website(id=1321427104911179915, webName=null, webTitle=null, webDomain=null, webCopyrigh=null, webIpcNo=null, seoTitle=null, seoKeywords=null, seoDescription=null, tenantJournalId=null, journalId=1319690329412173987, journalNameCn=null, journalNameEn=null, grayFlag=null, tenantId=1146029695717560320, platformId=null, journalGroupId=null, journalGroupNameCn=null, journalGroupNameEn=null, type=1, domain=https://castjournals.cast.org.cn/joweb/sjlcyw/CN, language=CN, createTime=1792982372739, createBy=18614031015, updateTime=1792982514949, updateBy=18614031015, name=世界临床药物-中文, tplId=1146099689490845704, title=世界临床药物, delFlag=0, indexPage=/home, props=[WebsiteProps(id=1321428428256031726, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=articleTextType, value=kx, createTime=1792982688249, updateTime=1792982688249, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428193117163, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=banner, value=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/file/pic?fileId=RR/csUBcM48ejcuaaK5s0g==, createTime=1792982688234, updateTime=1792982688234, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428302169073, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=grayFlag, value=0, createTime=1792982688260, updateTime=1792982688260, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428172145642, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=logo, value=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/file/pic?fileId=yyY2emcxcV1CfIeK9tH8ZA==, createTime=1792982688229, updateTime=1792982688229, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428327334899, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=minRunFlag, value=0, createTime=1792982688266, updateTime=1792982688266, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428226671597, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=picServerUrl, value=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/file/pic, createTime=1792982688242, updateTime=1792982688242, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428314751986, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=silenceFlag, value=0, createTime=1792982688263, updateTime=1792982688263, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428209894380, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=staticResourcePath, value=https://castjournals.cast.org.cn/joweb/cast_kjdb_cn_619/, createTime=1792982688238, updateTime=1792982688238, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428268614639, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=themeColor, value=null, createTime=1792982688252, updateTime=1792982688252, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428289586160, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=themeStyle, value=.style-1 .main-menu ul>li { margin-right: 18px; } @media (max-width: 1442px) { .style-1 .main-menu ul>li a { font-size: 16px; padding: 10px 0; } }, createTime=1792982688257, updateTime=1792982688257, creator=18614031015, updator=18614031015)]), Website(id=1321427104990871693, webName=null, webTitle=null, webDomain=null, webCopyrigh=null, webIpcNo=null, seoTitle=null, seoKeywords=null, seoDescription=null, tenantJournalId=null, journalId=1319690329412173987, journalNameCn=null, journalNameEn=null, grayFlag=null, tenantId=1146029695717560320, platformId=null, journalGroupId=null, journalGroupNameCn=null, journalGroupNameEn=null, type=1, domain=https://castjournals.cast.org.cn/joweb/sjlcyw/EN, language=EN, createTime=1792982372758, createBy=18614031015, updateTime=1792982556355, updateBy=18614031015, name=世界临床药物-英文, tplId=1146101810881728533, title=World Clinical Drug, delFlag=0, indexPage=/home, props=[WebsiteProps(id=1321428446820021244, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=articleTextType, value=kx, createTime=1792982692675, updateTime=1792982692675, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446757106681, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=banner, value=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/file/pic?fileId=RR/csUBcM48ejcuaaK5s0g==, createTime=1792982692660, updateTime=1792982692660, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428447109428223, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=grayFlag, value=0, createTime=1792982692744, updateTime=1792982692744, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446736135160, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=logo, value=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/file/pic?fileId=yyY2emcxcV1CfIeK9tH8ZA==, createTime=1792982692655, updateTime=1792982692655, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428447142981632, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=minRunFlag, value=0, createTime=1792982692752, updateTime=1792982692752, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446790661115, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=picServerUrl, value=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/file/pic, createTime=1792982692668, updateTime=1792982692668, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428447130399745, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=silenceFlag, value=0, createTime=1792982692749, updateTime=1792982692749, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446769689594, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=staticResourcePath, value=https://castjournals.cast.org.cn/joweb/cast_kjdb_en_623/, createTime=1792982692663, updateTime=1792982692663, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446832604157, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=themeColor, value=null, createTime=1792982692678, updateTime=1792982692678, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428447092651006, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=themeStyle, value=.style-1 .main-menu ul>li { margin-right: 18px; } @media (max-width: 1442px) { .style-1 .main-menu ul>li a { font-size: 16px; padding: 10px 0; } }, createTime=1792982692740, updateTime=1792982692740, creator=18614031015, updator=18614031015)])], journalTitle=世界临床药物, weixinUrl=null, journalUrl=http://www.jwph.com.cn/, iacademicId=null, status=1, seqNo=null, journalTitleEn=World Clinical Drug, journalPhotoCn=9c6IkcJKa1cF20h1u6lJeQ==, journalPhotoEn=MRqUlTwfL6oqIHNy7eyFZQ==, journalFirstLetter=S, journalRecommend=null, journalNew=null, journalCollection=null, jcrJf=null, cjcrJf=null, jcrJfStr=null, cjcrJfStr=null, submissionFirstDecision=null, sciSubjectClassification=null, casSubjectClassification=null, citeScore=null, totalCitationFrequency=null, icpCode=null, psCode=null, advertisingLicenseCode=null, copyrightInformation=null, country=null, option=, provinceCode=null, provinceName=null, collectFlag=false, interPubPlatform=, interPubPlatformUrl=null), detailUrlCn=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/10.13683/j.wph.2024.07.003, detailUrlEn=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/10.13683/j.wph.2024.07.003, pdfUrlCn=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/PDF/10.13683/j.wph.2024.07.003, pdfUrlEn=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/PDF/10.13683/j.wph.2024.07.003, aliStartDate=0, aliEndDate=0, collectionFlag=false, citedCount=null, citedUrl=null, previewStatus=0, delFlag=0, hasFullText=0, orderTime=1720540800000, fullTextJson=null, articleText=null, reference=null)
收藏切换
抗血管生成酪氨酸激酶抑制剂在实体瘤中的临床研究进展
徐蕊 1 , 钱佳佳 1 , 阮聪 1 , 王祺茹 1 , 翟青 1, 2, 3, *
世界临床药物 | 医药专论 2024,45(7): 710-718
收起
收藏切换
世界临床药物 |医药专论 2024 , 45 (7) : 710 -718
抗血管生成酪氨酸激酶抑制剂在实体瘤中的临床研究进展
全屏
[Author(id=1329529031680176684, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529030371553823, orderNo=0, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1329529031801811503, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529030371553823, authorId=1329529031680176684, language=EN, stringName=Rui XU, firstName=Rui, middleName=null, lastName=XU, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, address=1.Department of Pharmacy, Fudan University Shanghai Cancer Center Minhang Branch, Shanghai 200240, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1329529031915057712, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529030371553823, authorId=1329529031680176684, language=CN, stringName=徐蕊, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, address=1.复旦大学附属肿瘤医院闵行院区药剂科,上海 200240, bio={"content":"

徐蕊,主管药师,研究方向:肿瘤药学。

"}, bioImg=null, bioContent=

徐蕊,主管药师,研究方向:肿瘤药学。

, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1329529031340438050, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529030371553823, xref=1., ext=[AuthorCompanyExt(id=1329529031348826659, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529030371553823, companyId=1329529031340438050, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.Department of Pharmacy, Fudan University Shanghai Cancer Center Minhang Branch, Shanghai 200240, China), AuthorCompanyExt(id=1329529031386575396, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529030371553823, companyId=1329529031340438050, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.复旦大学附属肿瘤医院闵行院区药剂科,上海 200240)])]), Author(id=1329529032019915314, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529030371553823, orderNo=1, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1329529032158327348, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529030371553823, authorId=1329529032019915314, language=EN, stringName=Jiajia QIAN, firstName=Jiajia, middleName=null, lastName=QIAN, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, address=1.Department of Pharmacy, Fudan University Shanghai Cancer Center Minhang Branch, Shanghai 200240, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1329529032233824821, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529030371553823, authorId=1329529032019915314, language=CN, stringName=钱佳佳, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, address=1.复旦大学附属肿瘤医院闵行院区药剂科,上海 200240, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1329529031340438050, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529030371553823, xref=1., ext=[AuthorCompanyExt(id=1329529031348826659, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529030371553823, companyId=1329529031340438050, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.Department of Pharmacy, Fudan University Shanghai Cancer Center Minhang Branch, Shanghai 200240, China), AuthorCompanyExt(id=1329529031386575396, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529030371553823, companyId=1329529031340438050, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.复旦大学附属肿瘤医院闵行院区药剂科,上海 200240)])]), Author(id=1329529032309322295, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529030371553823, orderNo=2, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1329529032376431161, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529030371553823, authorId=1329529032309322295, language=EN, stringName=Cong RUAN, firstName=Cong, middleName=null, lastName=RUAN, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, address=1.Department of Pharmacy, Fudan University Shanghai Cancer Center Minhang Branch, Shanghai 200240, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1329529032456122938, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529030371553823, authorId=1329529032309322295, language=CN, stringName=阮聪, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, address=1.复旦大学附属肿瘤医院闵行院区药剂科,上海 200240, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1329529031340438050, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529030371553823, xref=1., ext=[AuthorCompanyExt(id=1329529031348826659, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529030371553823, companyId=1329529031340438050, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.Department of Pharmacy, Fudan University Shanghai Cancer Center Minhang Branch, Shanghai 200240, China), AuthorCompanyExt(id=1329529031386575396, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529030371553823, companyId=1329529031340438050, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.复旦大学附属肿瘤医院闵行院区药剂科,上海 200240)])]), Author(id=1329529032540009021, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529030371553823, orderNo=3, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1329529032598729279, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529030371553823, authorId=1329529032540009021, language=EN, stringName=Qiru WANG, firstName=Qiru, middleName=null, lastName=WANG, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, address=1.Department of Pharmacy, Fudan University Shanghai Cancer Center Minhang Branch, Shanghai 200240, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1329529032674226752, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529030371553823, authorId=1329529032540009021, language=CN, stringName=王祺茹, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, address=1.复旦大学附属肿瘤医院闵行院区药剂科,上海 200240, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1329529031340438050, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529030371553823, xref=1., ext=[AuthorCompanyExt(id=1329529031348826659, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529030371553823, companyId=1329529031340438050, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.Department of Pharmacy, Fudan University Shanghai Cancer Center Minhang Branch, Shanghai 200240, China), AuthorCompanyExt(id=1329529031386575396, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529030371553823, companyId=1329529031340438050, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.复旦大学附属肿瘤医院闵行院区药剂科,上海 200240)])]), Author(id=1329529032758112834, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529030371553823, orderNo=4, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=1, authorType=1, ext={EN=AuthorExt(id=1329529032900719174, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529030371553823, authorId=1329529032758112834, language=EN, stringName=Qing ZHAI, firstName=Qing, middleName=null, lastName=ZHAI, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, 2, 3, *, address=1.Department of Pharmacy, Fudan University Shanghai Cancer Center Minhang Branch, Shanghai 200240, China
2.Department of Pharmacy, Fudan University Shanghai Cancer Center, Shanghai 200032, China
3.Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1329529032967828039, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529030371553823, authorId=1329529032758112834, language=CN, stringName=翟青, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, 2, 3, *, address=1.复旦大学附属肿瘤医院闵行院区药剂科,上海 200240
2.复旦大学附属肿瘤医院药剂科,上海 200032
3.复旦大学上海医学院肿瘤学系,上海 200032, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1329529031340438050, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529030371553823, xref=1., ext=[AuthorCompanyExt(id=1329529031348826659, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529030371553823, companyId=1329529031340438050, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.Department of Pharmacy, Fudan University Shanghai Cancer Center Minhang Branch, Shanghai 200240, China), AuthorCompanyExt(id=1329529031386575396, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529030371553823, companyId=1329529031340438050, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.复旦大学附属肿瘤医院闵行院区药剂科,上海 200240)]), AuthorCompany(id=1329529031457878565, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529030371553823, xref=2., ext=[AuthorCompanyExt(id=1329529031470461478, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529030371553823, companyId=1329529031457878565, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.Department of Pharmacy, Fudan University Shanghai Cancer Center, Shanghai 200032, China), AuthorCompanyExt(id=1329529031478850087, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529030371553823, companyId=1329529031457878565, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.复旦大学附属肿瘤医院药剂科,上海 200032)]), AuthorCompany(id=1329529031550153256, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529030371553823, xref=3., ext=[AuthorCompanyExt(id=1329529031558541865, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529030371553823, companyId=1329529031550153256, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=3.Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China), AuthorCompanyExt(id=1329529031571124778, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529030371553823, companyId=1329529031550153256, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=3.复旦大学上海医学院肿瘤学系,上海 200032)])])]
徐蕊1, 钱佳佳1, 阮聪1, 王祺茹1, 翟青1, 2, 3, *
作者信息
  • 1.复旦大学附属肿瘤医院闵行院区药剂科,上海 200240
  • 2.复旦大学附属肿瘤医院药剂科,上海 200032
  • 3.复旦大学上海医学院肿瘤学系,上海 200032
通讯作者:
翟青,主任药师,博士研究生导师,研究方向:肿瘤药学。
作者简介:

徐蕊,主管药师,研究方向:肿瘤药学。

Clinical research progress of anti-angiogenic tyrosine kinase inhibitors in solid tumors
Rui XU1, Jiajia QIAN1, Cong RUAN1, Qiru WANG1, Qing ZHAI1, 2, 3, *
Affiliations
  • 1.Department of Pharmacy, Fudan University Shanghai Cancer Center Minhang Branch, Shanghai 200240, China
  • 2.Department of Pharmacy, Fudan University Shanghai Cancer Center, Shanghai 200032, China
  • 3.Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China
出版时间: 2024-07-10 doi: 10.13683/j.wph.2024.07.003
文章导航
收藏切换

新生血管的生成在多种实体肿瘤的生长、局部浸润以及远处转移中发挥关键作用。目前抗血管生成药物可为小分子多靶点、大分子单靶点和内源性泛靶点血管生成抑制剂3类。其中小分子抗血管生成抑制剂主要通过同时或序贯靶向多个生长因子/通路,从而抑制肿瘤血管新生,能有效抑制肿瘤细胞产生的耐药性。同时小分子抗血管生成抑制剂具有组织渗透性佳以及服用方便等优点,目前已被广泛用于多种实体肿瘤的联合治疗。该文对小分子抗血管生成酪氨酸激酶抑制剂的靶向治疗,以及其在多种实体瘤中的临床研究进展、安全性作一综述。

实体瘤  /  小分子  /  抗血管生成抑制剂  /  酪氨酸激酶抑制剂

Angiogenesis plays a key role in the growth, local invasion and distant metastasis of a variety of solid tumors. At present, anti-angiogenesis drugs can be divided into three types: small-molecule multi-target, macromolecule single-target and endogenous pan-target angiogenesis inhibitors. Among them, small molecule anti-angiogenesis inhibitors mainly inhibit tumor angiogenesis by simultaneously or sequentially targeting multiple growth factors/pathways, and can effectively inhibit drug resistance generated by tumor cells. At the same time, small molecule anti-angiogenesis inhibitors have the advantages of good tissue permeability and convenient administration. At present, it has been widely used in the combination therapy of various solid tumors. This paper reviewed the targeted therapy of small molecule anti-angiogenic tyrosine kinase inhibitors and their clinical progress and safety in multiple solid tumors.

solid tumors  /  small molecules  /  antiangiogenic inhibitors  /  tyrosine kinase inhibitors
徐蕊, 钱佳佳, 阮聪, 王祺茹, 翟青. 抗血管生成酪氨酸激酶抑制剂在实体瘤中的临床研究进展. 世界临床药物, 2024 , 45 (7) : 710 -718 . DOI: 10.13683/j.wph.2024.07.003
Rui XU, Jiajia QIAN, Cong RUAN, Qiru WANG, Qing ZHAI. Clinical research progress of anti-angiogenic tyrosine kinase inhibitors in solid tumors[J]. World Clinical Drug, 2024 , 45 (7) : 710 -718 . DOI: 10.13683/j.wph.2024.07.003
  • 上海市闵行区卫生健康系统优秀青年药学人才计划(mwyjyx03)
  • 上海市闵行区自然科学研究课题(2022MHZ040)
  • 上海市闵行区健康科普能力提升英才专项计划(MHJKKPYC-2023-10)
参考文献 引证文献
排序方式:
[1]
Qin S, Li A, Yi M, et al. Recent advances on anti-angiogenesis receptor tyrosine kinase inhibitors in cancer therapy[J]. J Hematol Oncol, 2019, 12(1): 27.
[2]
姜婧琦, 宋雨童, 卢育彤, 等. 抗血管生成靶向药物在肿瘤治疗中的研究进展[J]. 山东医药, 2022, 62(22): 86-90.
[3]
Li SJ, Chen JX, Sun ZJ. Improving antitumor immunity using antiangiogenic agents: mechanistic insights, current progress, and clinical challenges[J]. Cancer Commun (Lond), 2021, 41(9): 830-850.
[4]
Pu X, Xiao Z, Li J, et al. Anlotinib plus docetaxel vs docetaxel alone for advanced non-small-cell lung cancer patients who failed first-line treatment: a multicenter, randomized phase Ⅱtrial[J]. Lung Cancer, 2024, 191: 107538.
[5]
Zhang L, Wang L, Wang J, et al. Anlotinib plus icotinib as a potential treatment option for EGFR-mutated advanced non-squamous non-small cell lung cancer with concurrent mutations: final analysis of the prospective phase 2, multicenter ALTER-L004 study[J]. Mol Cancer, 2023, 22(1): 124.
[6]
Lu S, Chang J, Liu X, et al. Randomized, double-blind, placebocontrolled, multicenter phase Ⅱ study of fruquintinib after two prior chemotherapy regimens in Chinese patients with advanced nonsquamous nonsmall-cell lung cancer[J]. J Clin Oncol, 2018, 36(12): 1207-1217.
[7]
Lu S, Chen G, Sun Y, et al. A Phase Ⅲ, randomized, double-blind, placebo-controlled, multicenter study of fruquintinib in Chinese patients with advanced nonsquamous non-small-cell lung cancer—the FALUCA study[J]. Lung Cancer, 2020, 146: 252-262.
[8]
Xia H, Zhang H, Ruan Z, et al. Neoadjuvant camrelizumab (an anti-PD-1 antibody) plus chemotherapy or apatinib (a VEGFR-2 inhibitor) for initially unresectable stage Ⅱ—Ⅲnon-small-cell lung cancer: a multicentre, two-arm, phase 2 exploratory study[J]. Signal Transduct Target Ther, 2024, 9(1): 145.
[9]
Pu X, Lin G, Xiao M, et al. Camrelizumab combined with apatinib and nanoparticle albumin-bound paclitaxel in lung adenocarcinoma (CAPAP-lung): a single-arm phase Ⅱstudy[J]. EClinicalMedicine, 2024, 67: 102403.
[10]
Ma S, He Z, Liu Y, et al. Sintilimab plus anlotinib as second or further-line therapy for extensive disease small cell lung cancer: a phase 2 investigator-initiated non-randomized controlled trial[J]. EClinicalMedicine, 2024, 14(70): 102543.
[11]
Liu J, Liu Q, Li Y, et al. Efficacy and safety of camrelizumab combined with apatinib in advanced triple-negative breast cancer: an open-label phase Ⅱ trial[J]. J Immunother Cancer, 2020, 8(1): e000696.
[12]
Zeng T, Sun C, Liang Y, et al. A real-world multicentre retrospective study of low-dose apatinib for human epidermal growth factor receptor 2-negative metastatic breast cancer[J]. Cancers (Basel), 2022, 14(17): 4084.
[13]
Liu Y, Wang W, Yin R, et al. A phase 1 trial of fuzuloparib in combination with apatinib for advanced ovarian and triple-negative breast cancer: efficacy, safety, pharmacokinetics and germline BRCA mutation analysis[J]. Bio Med Central Med, 2023, 21(1): 376.
[14]
中国临床肿瘤协会(CSCO)妇科肿瘤专家委员会. 抗血管生成小分子酪氨酸激酶抑制剂在复发转移或晚期妇科肿瘤临床应用的中国专家共识(2022版)[J]. 中国癌症防治杂志, 2023, 15(1): 1-10.
[15]
Shen W, Jing C, Tian W, et al. Anlotinib in patients with recurrent platinum resistant/refractory ovarian cancer: a prospective, single arm, phase Ⅱ study[J]. Int J Gynecol Cancer, 2023, 33(11): 1764-1770.
[16]
Xu Q, Wang J, Sun Y, et al. Efficacy and safety of sintilimab plus anlotinib for PD-L1-positive recurrent or metastatic cervical cancer: a multicenter, single-arm, prospective phase Ⅱ trial[J]. J Clin Oncol, 2022, 40(16): 1795-1805.
[17]
Lan C, Shen J, Wang Y, et al. Camrelizumab plus apatinib in patients with advanced cervical cancer (CLAP): a multicenter, open-label, single-arm, phase Ⅱ trial[J]. J Clin Oncol, 2020, 38(34): 4095-4106.
[18]
谢玲玲, 林仲秋. 《2024NCCN子宫肿瘤临床实践指南(第1版)》解读[J]. 中国实用妇科与产科杂志, 2023, 39(11): 1122-1127.
[19]
Yuan G, Li Z, Ye F, et al. A multicenter, single-arm, phase 2 study of surufatinib plus toripalimab for patients with advanced endometrial cancer[EB/OL]. [2023-12-20]. https://meetings.asco.org/abstracts-presentations/223054
[20]
Li Y, Feng H, Ren P, et al. Safety and efficacy of apatinib monotherapy for unresectable, metastatic esophageal cancer: a single-arm, open-label, phase Ⅱ study[J]. Oncologist, 2020, 25(10): e1464-e1472.
[21]
Shen L, Lu M, Chen Z, et al. Phase Ⅱ trial of surufatinib plus toripalimab for disease progression after first-line chemotherapy with platinum and fluoropyrimidine in advanced gastric or gastroesophageal junction adenocarcinoma[EB/OL]. [2023-12-20]. https://meetings.asco.org/abstracts-presentations/199210
[22]
Yan T, Huang C, Peng C, et al. A multi-center retrospective study on the efficacy and safety of regorafenib vs. regorafenib combined with PD-1 inhibitors as a second-line therapy in patients with advanced hepatocellular carcinoma[J]. Ann Transl Med, 2023, 11(2): 109.
[23]
蔡宇, 赵长海, 罗利琼. 卡瑞利珠单抗联合安罗替尼治疗中晚期肝癌的疗效和安全性[J]. 循证医学, 2022, 22(4): 237-242.
[24]
Dai GH, Jia R, Si H, et al. A phase 1b/2 study of surufatinib plus camrelizumab, nab-paclitaxel, and S-1 (NASCA) as first-line therapy for metastatic pancreatic adenocarcinoma (mPDAC)[EB/OL]. [2023-12-20]. https://meetings.asco.org/abstracts-presentations/226583
[25]
Dasari A, Lonardi S, Garcia-Carbonero R, et al. Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study[J]. Lancet, 2023, 402(10395): 41-53.
[26]
Bourien H, Lamarca A, McNamara MG, et al. Druggable molecular alterations in bile duct cancer: potential and current therapeutic applications in clinical trials[J]. Expert Opin Investig Drugs, 2021, 30(9): 975-983.
[27]
中国临床肿瘤学会指南工作委员会. 中国临床肿瘤学会(CSCO)胆道恶性肿瘤诊疗指南2023[M]. 北京: 人民卫生出版社, 2023.
[28]
Goyal L, Meric-Bernstam F, Hollebecque A, et al. Futibatinib for FGFR2-rearranged intrahepatic cholangiocarcinoma[J]. N Engl J Med, 2023, 388(3): 228-239.
[29]
Maroto P, Porta C, Capdevila J, et al. Cabozantinib for the treatment of solid tumors: a systematic review[J]. Ther Adv Med Oncol, 2022, 14: 17588359221107112.
[30]
Chen J, Ji Q, Bai C, et al. Surufatinib in Chinese patients with locally advanced or metastatic differentiated thyroid cancer and medullary thyroid cancer: a multicenter, open-label, phase Ⅱ trial[J]. Thyroid, 2020, 30(9): 1245-1253.
[31]
Chen JY, Huang NS, Wei WJ, et al. The efficacy and safety of surufatinib combined with anti PD-1 antibody toripalimab in neoadjuvant treatment of locally advanced differentiated thyroid cancer: a phase Ⅱ study[J]. Ann Surg Oncol, 2023, 30(12): 7172-7180.
[32]
Dierks C, Seufert J, Aumann K, et al. Combination of lenvatinib and pembrolizumab is an effective treatment option for anaplastic and poorly differentiated thyroid carcinoma[J]. Thyroid, 2021, 31(7): 1076-1085.
[33]
中国临床肿瘤学会指南工作委员会. 中国临床肿瘤学会(CSCO)软组织肉瘤诊疗指南(2022)[M]. 北京: 人民卫生出版社, 2022.
[34]
Xu B, Pan Q, Pan H, et al. Anlotinib as a maintenance treatment for advanced soft tissue sarcoma after first-line chemotherapy (ALTER-S006): a multicentre, open-label, single-arm, phase 2 trial[J]. EClinicalMedicine, 2023, 64: 102240.
[35]
Liu Z, Wang X, Wang J, et al. Gemcitabine plus anlotinib is effective and safe compared to gemcitabine plus docetaxel in advanced soft tissue sarcoma[J]. Front Oncol, 2022, 12: 922127.
[36]
Endo M, Kataoka T, Fujiwara T, et al. Protocol for the 2ND-STEP study, Japan Clinical Oncology Group study JCOG1802: a randomized phase Ⅱ trial of second-line treatment for advanced soft tissue sarcoma comparing trabectedin, eribulin and pazopanib[J]. Bio Med Central Cancer, 2023, 23(1): 219.
[37]
Penel N, Mir O, Wallet J, et al. A double-blind placebo controlled randomized phase Ⅱ trial assessing the activity and safety of regorafenib in non-adipocytic sarcoma patients previously treated with both chemotherapy and pazopanib[J]. Eur J Cancer, 2020, 126: 45-55.
[38]
Motzer RJ, Porta C, Eto M, et al. Lenvatinib plus pembrolizumab versus sunitinib in first-line treatment of advanced renal cell carcinoma: final prespecified overall survival analysis of CLEAR, a phase Ⅲ study[J]. J Clin Oncol, 2024, 42(11): 1222-1228.
[39]
李长岭, 齐隽, 陈立军, 等. 晚期肾透明细胞癌一线靶向治疗的优化选择中国专家共识(2022)[J]. 临床泌尿外科杂志, 2022, 37(5): 329-337.
[40]
Loriot Y, Matsubara N, Park SH, et al. Erdafitinib or chemotherapy in advanced or metastatic urothelial carcinoma[J]. N Engl J Med, 2023, 389(21): 1961-1971.
[41]
Liang H, Jiang YF, Liu GY, et al. Camrelizumab and apatinib plus induction chemotherapy and concurrent chemoradiotherapy in stage N3 nasopharyngeal carcinoma: a phase 2 clinical trial[J]. Nat Commun, 2024, 15(1): 1029.
[42]
Ding X, Zhang WJ, You R, et al. Camrelizumab plus apatinib in patients with recurrent or metastatic nasopharyngeal carcinoma: an open-label, single-arm, phase Ⅱ study[J]. J Clin Oncol, 2023, 41(14): 2571-2582.
[43]
Ding X, Hua YJ, Zou X, et al. Camrelizumab plus famitinib in patients with recurrent or metastatic nasopharyngeal carcinoma treated with PD-1 blockade: data from a multicohort phase 2 study[J]. EClinicalMedicine, 2023, 61: 102043.
[44]
Cao Y, Langer R, Ferrara N. Targeting angiogenesis in oncology, ophthalmology and beyond. Nat Rev Drug Discov, 2023, 22(6): 476-495.
[45]
Zhao Q, Wu ZE, Li B, et al. Recent advances in metabolism and toxicity of tyrosine kinase inhibitors[J]. Pharmacol Ther, 2022, 237: 108256.
2024年第45卷第7期
17
5
0
引用本文
BibTeX
文章信息
doi: 10.13683/j.wph.2024.07.003
  • 接收时间:2024-04-30
  • 首发时间:2026-11-17
  • 出版时间:2024-07-10
补充材料
相关文章
文章信息
作者
出版历史
  • 收稿日期:2024-04-30
基金
上海市闵行区卫生健康系统优秀青年药学人才计划(mwyjyx03)
上海市闵行区自然科学研究课题(2022MHZ040)
上海市闵行区健康科普能力提升英才专项计划(MHJKKPYC-2023-10)
作者信息
    1.复旦大学附属肿瘤医院闵行院区药剂科,上海 200240
    2.复旦大学附属肿瘤医院药剂科,上海 200032
    3.复旦大学上海医学院肿瘤学系,上海 200032

通讯作者:

翟青,主任药师,博士研究生导师,研究方向:肿瘤药学。
参考文献
分享链接
https://castjournals.cast.org.cn/joweb/sjlcyw/CN/10.13683/j.wph.2024.07.003
分享至
全文二维码

扫描看全文

引用本文
BibTeX
本文的引用情况
2种不同金属材料的力学参数
科
Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)
属
Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏